logo
Girls' basketball notebook: In memory of loved ones, Lincoln-Sudbury teams up in Hoops 4 Hope

Girls' basketball notebook: In memory of loved ones, Lincoln-Sudbury teams up in Hoops 4 Hope

Boston Globe28-01-2025

The Warriors (10-2), ranked 18th in this week's Globe Top 20, earned a 46-40 win over Bridgewater-Raynham and raised $1,800 in the process. They'll distribute the money evenly to the National Brain Tumor Society and the Pediatric Brain Tumor Foundation.
They also created a 'Hope Wall' outside the gym, where people could sign and leave notes and names of family members and friends who have battled all types of cancer.
Get Starting Point
A guide through the most important stories of the morning, delivered Monday, Wednesday, and Friday.
Enter Email
Sign Up
While it was certainly an emotional evening, it wasn't necessarily a somber one. The senior Schwartz and the two juniors know their relatives would have wanted them to continue to play with joy, even in their absence.
Advertisement
'It wasn't about despair and sadness,' Lincoln-Sudbury coach
Howie Landau
said. 'It was about happiness, and the emotion of bringing the community together.'
When Poland, Wallerstein, and members of the L-S volleyball team conducted an event for breast cancer awareness last fall, they decided they should try to do something similar for basketball. With their shared experiences as a driving force, they worked diligently to launch the plan.
'It's definitely affected us as a team and a program, so I thought this would be a really special moment,' Poland said.
Landau was completely for the idea, and together they started to spread the word. He's grateful to the Lincoln-Sudbury community and administration, plus coach
Cheryl Seavey
and the Bridgewater-Raynham program, for helping to turn it into a reality.
L-S athletic director
Dan Lee
said he's always impressed at the initiative and social awareness of the school's student-athletes. He said the planning of this night was student-driven and is a wonderful example of how student-athletes can use the platform of sport to bring initiatives to the broader community.
Advertisement
'What makes the Lincoln-Sudbury community special is its unwavering spirit of unity and compassion, exemplified through events like Hoops 4 Hope,' Lee said. 'These initiatives reflect the heart of our community — where people come together not just to raise awareness, but to actively support and honor causes that make a lasting impact.'
Schwartz, who has raised money through the cancer research organization 'A Shot For Life' with her brother,
Ben
, is grateful to have multiple communities that provide hope. She continues to think of her father every step of the way as she gives back.
'Playing basketball kind of became a way for us to keep his memory alive,' Schwartz said.
Schwartz, averaging 12.6 points, 6.4 rebounds, and 4 assists per game, said her father used to love Eminem's song 'Lose Yourself.' He played it before he got chemo and had surgery as a way to get himself in the right frame of mind, and she still thinks of it often before she competes.
Lincoln-Sudbury's Evie Schwartz, (32), pictured dishing a pass against Bridgewater-Raynham, lost her father, Ken, to brain cancer in 2021. 'Playing basketball kind of became a way for us to keep his memory alive,' she said.
Barry Chin/Globe Staff
Wallerstein, contributing 9.5 points, 8.1 rebounds, and 1.7 blocks a night, wears No. 21 in honor of her sister. She designed the T-shirts for the event and made sure to set the tone Friday.
'When my sister was going through everything, she was never sad,' Wallerstein said. 'She was always upbeat. I want to make sure everyone on the team is smiling and having a fun time, even though it was an emotional night.'
Landau said Wallerstein's mother,
Elin
, told him that Alice's 3-year-old sister,
Iris
, got really excited in the crowd when she heard Lea's name.
Poland, averaging 12.7 points, 8.1 rebounds, and 3.6 assists, has seen the way her grandfather's death affected her mother. She views basketball as an outlet to 'let everything out' and used the event as a way to honor his legacy.
Advertisement
All three mothers and all three players have bonded through shared grief. When Schwartz, Poland, and Wallerstein each made the team, their separate but overlapping experiences were critical in bringing them together.
As devastating as each loss has been, the heartbreak they've endured has helped them grasp the fragility of life and the value of family.
'We're all close even without it, but it's brought us closer,' Wallerstein said.
Lincoln-Sudbury's Sarah Poland, (22), drawing a host of Bridgewater-Raynham defenders on a drive, views basketball as an outlet to 'let everything out,' and used the Hoops 4 Hope event as a way to honor her grandfather's legacy.
Barry Chin/Globe Staff
Alice Wallerstein (21), driving through a B-R double team, said her late sister, Lea, was never sad. She "was always upbeat. I want to make sure everyone on the team is smiling and having a fun time, even though it was an emotional night.'
Barry Chin/Globe Staff
Courtside chatter
▪ An impact player on varsity since she first stepped on the court at Notre Dame (Hingham) as a seventh grader,
Ava Orlando
joined the notable 2,000-point club with her 31-point, 10-assist, 6-steal performance in Friday's 79-44 nonleague win over Longmeadow. Only 81 other players in state have reached the lofty total.
'It was great to see my teammates so happy for me,' said Orlando, who surpassed the milestone with a second-quarter 3-pointer in transition. 'Hopefully we can continue to make memories with our tournament run.'
Orlando can think on a dime mid-dribble, which is how she generates scoring.
'I let the opponent guess what I'm doing next,' Orlando said. 'Just with my overall IQ, knowing when to go and not to go, and moving the ball around me plays into it.'
On Tuesday, NDA will honor Orlando before the Cougars take on Fontbonne at 6:30 p.m.
▪ With five key players sidelined, Blue Hills is making up for its losses with a 'next-person up' approach. Freshman center
Sarah Michel
, for one, is playing like a veteran.
The 5-foot-10-inch underclassman is leading the Warriors (12-0) with 16.9 points and 11 rebounds per game.
Advertisement
'She kind of does it all for us right now,' coach
Nicole Flynn
said.
In a Mayflower Athletic Conference win over Bristol-Plymouth last Tuesday, Michel netted a career-high 27 points. In the following two games, she combined for another 32.
'She definitely scores really well down low, but there are other times where she'll rebound and go on a fastbreak,' said Flynn. 'She has the ability to go coast to coast, and she definitely is someone who the bigger the game is, the better she performs.'
▪ With four returning starters, plus the first reserve off the bench, Bourne (12-1) sits atop the South Coast Conference.
Coach
Steve Wenzel
has a number of options, with senior captains
Paige Meda
(16.5 points per game) and
McKinley Wenzel
(12.5 ppg), his daughter, spearheading the operation.
'We play a multitude of offenses depending on what we're seeing,' Wenzel said. 'We can spread, high-screen roll, or we can run sets, the old-school two in the posts and three guards dump it in. I have some high-level IQ forwards, so our inside-out game is pretty solid.'
Junior bigs
Raeghan Blake
and
Nola Timo
average 8 rebounds per game, and junior guard
Aubrey France
averages 6 steals, leading the league.
'From tryouts to launching the season, we've really been ahead of schedule,' Wenzel said. 'That's really been the key.'
Games to watch
Tuesday, No. 3 Woburn at Reading, 7 p.m.
— A matchup of the top two teams in the Middlesex League's Liberty Division.
Friday, No. 11 Braintree at Walpole, 6 p.m.
— The Timberwolves have had their moments, but the hosts will need to be at their best in this Bay State-Herget showdown.
Advertisement
Friday, No. 15 Pembroke at No. 16 North Quincy
— In a stacked Patriot-Fisher division, two of the top three teams go head-to-head in this top-20 matchup.
Friday, Framingham at No. 14 Natick, 6:30 p.m.
— The Flyers have stood out with wins against Lincoln-Sudbury and Natick early in the season, making this an intriguing matchup.
Saturday, No. 8 Dartmouth at No. 4 St. Mary's, 7 p.m.
— This nonleague contest features two of the state's most prolific squads.
Correspondent Graham Dietz contributed to this story.
Trevor Hass can be reached at

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Sports on TV for Tuesday, June 10
Sports on TV for Tuesday, June 10

San Francisco Chronicle​

timean hour ago

  • San Francisco Chronicle​

Sports on TV for Tuesday, June 10

(All times Eastern) Schedule subject to change and/or blackouts Tuesday, June 10 MLB BASEBALL 7:30 p.m. TBS — N.Y. Yankees at Kansas City 10:30 p.m. MLBN — Regional Coverage: Seattle at Arizona (9:40 p.m.) OR L.A. Dodgers at San Diego (9:40 p.m.) SOCCER (MEN'S) 11:50 a.m. FS2 — International Friendly: Azerbaijan vs. Hungary, Mardakan, Azerbaijan 2:30 p.m. FS2 — UEFA World Cup Qualifier Group Stage: Netherlands vs. Malta, Group G, Groningen, Netherlands 8 p.m. TNT — International Friendly: U.S. vs. Switzerland, Nashville, Tenn. SOFTBALL 8 p.m. ESPN2 — Athletes Unlimited: Talons vs. Bandits, Rosemont, Ill. 5 a.m. 6 a.m. TENNIS — s-Hertogenbosch-ATP/WTA, London-WTA, Stuttgart-ATP Early Rounds 5 a.m. (Wednesday) 6 a.m. (Wednesday) TENNIS — s-Hertogenbosch-ATP/WTA, London-WTA, Stuttgart-ATP Early Rounds WNBA BASKETBALL 8 p.m. ESPN — Chicago at New York _____ The Associated Press created this story using technology provided by Data Skrive TV listings provided by LiveSportsOnTV.

Josh Pate isn't sleeping on Oklahoma's John Mateer
Josh Pate isn't sleeping on Oklahoma's John Mateer

USA Today

timean hour ago

  • USA Today

Josh Pate isn't sleeping on Oklahoma's John Mateer

Josh Pate isn't sleeping on Oklahoma's John Mateer The Oklahoma Sooners made a major upgrade at starting quarterback this winter. With former starter Jackson Arnold off to play for the Auburn Tigers, OU had a hole to fill under center. Not only did they fill it, they did so with a player, John Mateer, who is better than any QB the Sooners had on the roster a year ago. In fact, Mateer was the transfer portal's top overall player this year. Oklahoma beat out Miami and North Carolina to land the former Washington State star. After OU was atrocious offensively in 2024, Mateer's arrival gives the Sooners a chance to rebound back to their winning ways in 2025. At least that's what Josh Pate, the host of "Josh Pate's College Football Show", thinks. Because of familiarity with his play-caller and the help of players from multiple top-ten recruiting classes over the past few years, he has Mateer right alongside the best quarterbacks in the entire SEC. "I'm putting John Mateer in the top five," Pate said. "If I'm right, Oklahoma's gonna be a contender in the SEC. I believe in the OC-quarterback approach, bringing both of them in, not just one of them, especially when they're both qualified, and Ben Arbuckle and John Mateer are. I also think it greatly helps that John Mateer is not being brought into Norman, Oklahoma, and then being looked at by everyone down on their knees with their hands clasped praying, 'Please save us John, save us.' No, you don't need to save anyone. You need to go in there and play solid football and execute, make good decisions, because you know what you've got around you? You've got a top-ten roster around you. You've got a really good defense. You don't have to score 42 a game to win, and you've got guys calling plays for you that you're very familiar with. I think he's gonna be really good this year. That's why I've got Oklahoma top ten in the preseason." Sooner Nation has long clamored for complementary football in Norman. For years, OU fans had to watch incredible offenses, led by Heisman Trophy-level quarterbacks, be ultimately let down by bad defenses. The trio of Baker Mayfield, Kyler Murray and Jalen Hurts combined for four College Football Playoff appearances in five seasons from 2015 to 2019, and it was the inability to get stops on defense that, for the most part, sunk those excellent Oklahoma teams in the semifinal round each time. When Brent Venables took over for Lincoln Riley, the hope was that he could change that. In the years since, Venables has built up a defense that looks like it can compete in the SEC. But, just as the defense was getting really good in 2024, Oklahoma's offense fell off a cliff with Seth Littrell and Jackson Arnold at the helm. Complementary football eluded OU yet again. With plenty of returning starters, the Oklahoma defense looks like it has the pieces to be good again. On the other side of the ball, the Arbuckle-Mateer combination hopes to finally bring high-level play on both offense and defense, at the same time, to Norman in 2025. Contact/Follow us @SoonersWire on X, and like our page on Facebook to follow ongoing coverage of Oklahoma news, notes, and opinions. You can also follow Aaron on X @Aaron_Gelvin.

TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial
TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial

Yahoo

time5 hours ago

  • Yahoo

TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial

- For the TransCon CNP treatment-naïve cohort, combination treatment resulted in mean annualized growth velocity (AGV) of 9.14 cm/year, with an improvement in mean ACH height Z-score of +0.53 over 26 weeks - For the TransCon CNP-treated cohort, combination treatment resulted in mean AGV of 8.25 cm/year, with an improvement in mean ACH height Z-score of +0.44 over 26 weeks - The combination of TransCon hGH and TransCon CNP demonstrated accelerated improvement in body proportionality at Week 26, aligning with the increase in linear growth - Safety and tolerability data consistent with those observed for TransCon hGH and TransCon CNP monotherapies; combination treatment was generally well tolerated, with generally mild treatment-emergent adverse events (TEAEs) - Ascendis to host conference call today at 8:00 am ET COPENHAGEN, Denmark, June 09, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced Week 26 interim analysis results from its ongoing COACH Trial, the first clinical trial to evaluate combination treatment with once-weekly investigational TransCon CNP (navepegritide) and once-weekly TransCon hGH (lonapegsomatropin) in children with achondroplasia. Results demonstrated that TransCon hGH boosted treatment benefits of TransCon CNP, resulting in significant growth and proportionality improvements in children with achondroplasia after 26 weeks of combination treatment, with a safety and tolerability profile consistent with those observed for TransCon hGH and TransCon CNP monotherapies. TransCon CNP, which is under priority review as a monotherapy for children with achondroplasia by the U.S. Food & Drug Administration (FDA), is an investigational prodrug of C-type natriuretic peptide (CNP) administered once weekly, providing continuous exposure of active CNP to receptors on tissues throughout the body, including growth plates and skeletal muscle. TransCon hGH is a prodrug of somatropin administered once weekly, providing sustained release of active, unmodified somatropin. TransCon hGH is approved and marketed as SKYTROFA® for the treatment of pediatric growth hormone deficiency and is in development for other indications. 'TransCon CNP as a monotherapy has demonstrated the potential to transform the treatment of achondroplasia, and the COACH Trial at Week 26 demonstrates that TransCon hGH has the potential to boost treatment benefits of TransCon CNP with a safety profile consistent with monotherapies,' said Aimee Shu, M.D., Executive Vice President of Endocrine & Rare Disease Medical Sciences and Chief Medical Officer at Ascendis Pharma. 'These results highlight the unique portfolio of once-weekly TransCon CNP and once-weekly TransCon hGH, with complementary modes of action, to improve the treatment landscape for growth disorders and physical functioning.' COACH Trial DesignThe COACH Trial is an ongoing proof-of-concept prospective Phase 2 open-label trial to investigate the efficacy, safety, and tolerability of combined treatment with once-weekly TransCon CNP at 100 µg/kg/week and once-weekly TransCon hGH at 0.30 mg/kg/week in children with achondroplasia aged 2 to 11 years. The trial included a cohort of TransCon CNP treatment naïve children (N=12, mean age 4.67 years) and a cohort of TransCon CNP-treated children (N=9, mean age 7.89 years) who had received TransCon CNP (100 µg/kg/week) for a mean of 2.56 years in clinical trials. The trial population is representative of children with achondroplasia, except for the observed growth benefit in the TransCon CNP-treated cohort. The interim analysis will be followed by Week 52 data, expected in Q4 2025, and Ascendis plans to initiate a Phase 3 trial in Q4 2025. Highlights of the Interim Topline Week 26 COACH Trial Results For TransCon CNP treatment-naïve children, mean annualized growth velocity (AGV) was 9.14 cm/year, representing an increase from baseline at Week 26 of 4.23 cm/year, with an improvement in mean ACH height Z-score of +0.53 over 26 weeks. For TransCon CNP-treated children, mean AGV was 8.25 cm/year, representing an increase from baseline at Week 26 of 3.10 cm/year, with an improvement in mean ACH height Z-score of +0.44 over 26 weeks. Mean AGV with TransCon CNP and TransCon hGH combination treatment exceeded the 97th percentile of average-stature children. Children treated with TransCon hGH and TransCon CNP demonstrated accelerated improvement in body proportionality at Week 26, aligning with the increase in linear growth. Bone age advanced in line with chronologic age. Safety and tolerability data were consistent with those observed for TransCon hGH and TransCon CNP monotherapies; combination treatment was generally well tolerated, with generally mild TEAEs. A slide presentation with these data can be found on the Investor Relations & News section of the Ascendis Pharma website: Conference Call and Webcast InformationAscendis Pharma will host a conference call and webcast today at 8:00 am Eastern Time (ET) to discuss these results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at A replay of the webcast will be available on that page shortly after the conclusion of the event for 30 days. About AchondroplasiaAchondroplasia is a rare genetic condition arising from a systemic fibroblast growth factor receptor 3 (FGFR3) variant that leads to an imbalance in the effects of the FGFR3 and CNP signaling pathways, estimated to affect more than 250,000 people worldwide. While historically considered a bone growth disorder, the FGFR3 variant seen in achondroplasia is expressed in tissues throughout the body, causing serious muscular, neurological, and cardiorespiratory complications in addition to skeletal dysplasia. Medical complications of achondroplasia vary across different stages of life. Throughout infancy and childhood, observed complications include spinal deformities, enlarged brain ventricles, impaired muscle strength and stamina, hearing deficits and chronic ear infections, upper airway obstructions, sleep-disordered breathing, hip problems, leg bowing, and chronic pain; many of these persist or worsen in adulthood. These medical complications can have detrimental effects on quality of life, physical functioning, and psychosocial function. Individuals with achondroplasia often require multiple surgeries and procedures to alleviate the condition's many complications. About Ascendis Pharma A/SAscendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit to learn more. Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis' future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) TransCon CNP's potential to transform the treatment of achondroplasia, (ii) TransCon hGH's potential to boost treatment benefits of TransCon CNP with a safety profile consistent with monotherapies, (iii) the potential for the combination of TransCon CNP and TransCon hGH to improve the treatment landscape for growth disorders and physical functioning, (iv) the expected timing of Week 52 data from the COACH Trial and Ascendis' plans to initiate a Phase 3 trial in Q4 2025, (v) Ascendis' ability to apply its TransCon technology platform to make a meaningful difference for patients, and (vi) Ascendis' application of its TransCon technologies to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis' products and product candidates; unforeseen safety or efficacy results in Ascendis' development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis' development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis' business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis' ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors, including tariffs and trade policies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis' business in general, see Ascendis' Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 12, 2025, and Ascendis' other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law. Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, SKYTROFA, and TransCon are trademarks owned by the Ascendis Pharma group. © June 2025 Ascendis Pharma A/S. Investor Contacts: Media Contact: Sarada Weerasinghe Melinda Baker Ascendis Pharma Ascendis Pharma ir@ media@ Patti Bank ICR Healthcare +1 (415) 513-1284 Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store